Sutro Biopharma

Sutro Biopharma is a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF?, to create a variety of protein therapeutics initially for cancer and autoimmune disorders. The company's two product candidates are wholly owned: STRO-001, an antibody-drug conjugates (ADC) directed against CD74, for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
  • TickerSTRO
  • ISINUS8693671021
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+3)
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+3)
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+3)
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus

ResearchPool Subscriptions

Get the most out of your insights

Get in touch